TONIX PHARMACEUTICALS HOLDING CORP

Inactive Instrument

Highlights Tonix Pharmaceuticals Holding Corp Nasdaq

Equities

US8902604094

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble	Mar. 28	MT
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome	Mar. 25	MT
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting	Mar. 21	CI
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial	Mar. 11	CI
Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy	Mar. 07	CI
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans	Mar. 05	CI
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers	Feb. 28	CI
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya? to Support Development and Partnering in Japan and China	Feb. 27	CI
Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December	Feb. 15	CI
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya?, Plans to File NDA for FDA Approval in Second Half of 2024	Feb. 14	CI
Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD	Feb. 12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer